Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHGCY Chugai Pharmaceutical	$22.87 -1.7%	$25.69	$18.39 ▼ $31.26	$76.55B	0.66	272,834 shs	542,221 shs
DSNKY Daiichi Sankyo	$22.75 +1.0%	$24.21	$20.92 ▼ $42.48	$42.66B	N/A	226,141 shs	293,826 shs
TAK Takeda Pharmaceutical	$14.74 -2.0%	$14.83	$12.80 ▼ $15.53	$47.86B	0.23	2.02 million shs	3.70 million shs
ZTS Zoetis	$152.88 -1.8%	$161.33	$139.70 ▼ $200.33	$69.30B	0.91	2.60 million shs	3.27 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHGCY Chugai Pharmaceutical	-1.68%	-2.76%	-11.73%	-4.35%	+14.98%
DSNKY Daiichi Sankyo	+1.02%	+6.51%	-7.52%	+3.64%	-40.12%
TAK Takeda Pharmaceutical	-2.00%	-1.90%	-3.06%	+0.44%	+10.04%
ZTS Zoetis	-1.80%	-3.07%	-6.93%	+4.16%	-14.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHGCY Chugai Pharmaceutical	1.4849 of 5 stars	0.0	3.0	2.5	0.0	2.2	0.0	1.3
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	2.0393 of 5 stars	0.0	5.0	2.5	0.0	2.9	0.0	0.6
ZTS Zoetis	4.8823 of 5 stars	3.5	5.0	4.2	0.4	3.1	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHGCY Chugai Pharmaceutical	0.00	N/A	N/A	N/A
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
ZTS Zoetis	3.00	Buy	$212.13	38.75% Upside

Current Analyst Ratings Breakdown

Latest CHGCY, ZTS, TAK, and DSNKY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHGCY Chugai Pharmaceutical	$7.74B	9.72	$0.83 per share	27.63	$3.81 per share	6.00
DSNKY Daiichi Sankyo	$12.39B	3.48	$1.27 per share	17.94	$5.61 per share	4.06
TAK Takeda Pharmaceutical	$30.09B	1.56	$3.12 per share	4.73	$14.39 per share	1.02
ZTS Zoetis	$9.26B	7.35	$6.95 per share	22.01	$10.57 per share	14.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHGCY Chugai Pharmaceutical	$2.56B	$0.81	28.23	29.32	N/A	33.56%	21.71%	18.98%	7/24/2025 (Estimated)
DSNKY Daiichi Sankyo	$1.95B	$1.03	22.09	20.87	1.16	15.65%	17.92%	8.61%	7/29/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	66.98	8.93	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	27.45	22.65	2.58	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest CHGCY, ZTS, TAK, and DSNKY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ZTS Zoetis	$1.61	N/A	N/A	N/A	$2.41 billion	N/A
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/25/2025	Q4 2025	DSNKY Daiichi Sankyo	N/A	$0.30	N/A	$0.30	N/A	$3.40 billion
4/24/2025	Q1 2025	CHGCY Chugai Pharmaceutical	N/A	$0.19	N/A	$0.19	N/A	$1.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHGCY Chugai Pharmaceutical	$0.26	1.14%	N/A	32.10%	N/A
DSNKY Daiichi Sankyo	$0.29	1.27%	N/A	28.16%	N/A
TAK Takeda Pharmaceutical	$0.55	3.73%	N/A	250.00%	N/A
ZTS Zoetis	$2.00	1.31%	N/A	35.91%	14 Years

Latest CHGCY, ZTS, TAK, and DSNKY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHGCY Chugai Pharmaceutical	N/A	7.28	6.16
DSNKY Daiichi Sankyo	0.06	2.53	1.85
TAK Takeda Pharmaceutical	0.57	1.01	0.52
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHGCY Chugai Pharmaceutical	0.01%
DSNKY Daiichi Sankyo	N/A
TAK Takeda Pharmaceutical	9.17%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
CHGCY Chugai Pharmaceutical	N/A
DSNKY Daiichi Sankyo	N/A
TAK Takeda Pharmaceutical	0.04%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHGCY Chugai Pharmaceutical	7,778	3.29 billion	N/A	Not Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
ZTS Zoetis	13,800	445.21 million	444.50 million	Optionable

CHGCY, ZTS, TAK, and DSNKY Headlines

Recent News About These Companies

Zoetis Inc. (NYSE:ZTS) Shares Sold by Dakota Wealth Management

July 14 at 8:57 AM | marketbeat.com

Sumitomo Life Insurance Co. Acquires 14,553 Shares of Zoetis Inc. (NYSE:ZTS)

July 14 at 8:45 AM | marketbeat.com

OVERSEA CHINESE BANKING Corp Ltd Has $148.23 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

July 14 at 8:20 AM | marketbeat.com

Baer Investment Advisory LLC Takes $2.10 Million Position in Zoetis Inc. (NYSE:ZTS)

July 14 at 8:18 AM | marketbeat.com

Edgestream Partners L.P. Has $9.16 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

July 14 at 7:04 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Turtle Creek Wealth Advisors LLC

July 14 at 6:50 AM | marketbeat.com

BHK Investment Advisors LLC Acquires Shares of 3,452 Zoetis Inc. (NYSE:ZTS)

July 14 at 6:19 AM | marketbeat.com

MQS Management LLC Buys New Position in Zoetis Inc. (NYSE:ZTS)

July 14 at 6:17 AM | marketbeat.com

Schechter Investment Advisors LLC Has $1.79 Million Stake in Zoetis Inc. (NYSE:ZTS)

July 14 at 5:32 AM | marketbeat.com

New York State Common Retirement Fund Has $92.51 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

July 14 at 5:21 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Mutual of America Capital Management LLC

July 14 at 5:20 AM | marketbeat.com

Berkeley Inc Takes Position in Zoetis Inc. (NYSE:ZTS)

July 13 at 7:54 AM | marketbeat.com

Rainey & Randall Wealth Advisors Inc. Invests $274,000 in Zoetis Inc. (NYSE:ZTS)

July 13 at 7:11 AM | marketbeat.com

Stephens Inc. AR Increases Stake in Zoetis Inc. (NYSE:ZTS)

July 13 at 6:25 AM | marketbeat.com

Arizona State Retirement System Acquires 4,794 Shares of Zoetis Inc. (NYSE:ZTS)

July 13 at 5:31 AM | marketbeat.com

Platform Technology Partners Grows Stake in Zoetis Inc. (NYSE:ZTS)

July 12, 2025 | marketbeat.com

Harmony Asset Management LLC Takes Position in Zoetis Inc. (NYSE:ZTS)

July 12, 2025 | marketbeat.com

Cerity Partners LLC Has $40.56 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

July 12, 2025 | marketbeat.com

Zoetis Stock Guidance | NYSE:ZTS | Benzinga

July 11, 2025 | benzinga.com

Zoetis Inc. (NYSE:ZTS) is Ownership Capital B.V.'s 7th Largest Position

July 11, 2025 | marketbeat.com

Diversify Wealth Management LLC Has $4.64 Million Position in Zoetis Inc. (NYSE:ZTS)

July 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Applied Digital: Now the High-Stakes Race to Build Begins
By Jeffrey Neal Johnson | June 17, 2025
View Applied Digital: Now the High-Stakes Race to Build Begins
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks
The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
By Leo Miller | July 2, 2025
View The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding

CHGCY, ZTS, TAK, and DSNKY Company Descriptions

Chugai Pharmaceutical OTCMKTS:CHGCY

$22.87 -0.39 (-1.68%)

As of 07/15/2025 04:00 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Daiichi Sankyo OTCMKTS:DSNKY

$22.75 +0.23 (+1.02%)

As of 07/15/2025 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical NYSE:TAK

$14.74 -0.31 (-2.03%)

Closing price 07/15/2025

Extended Trading

$14.74 +0.01 (+0.07%)

As of 07/15/2025 07:50 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Zoetis NYSE:ZTS

$152.88 -2.77 (-1.78%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$152.50 -0.38 (-0.25%)

As of 07/15/2025 07:47 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time